Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details Narrative)

v3.22.1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Mar. 19, 2018
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $ 11,958,145 $ 15,414,807  
Federal operating loss carryforward 5,740,342 2,648,248  
Deferred tax asset, start-up expenditures 3,172,746 1,345,002  
Allocated stock based compensation 1,580,984 383,571  
Deferred tax asset, intangible asset 788,495    
Deferred tax liability, intangible assets 2,145,620 2,433,959  
Non-deductibility of the amortization of the intangible asset 2,145,620    
Income Tax Expense (Benefit) 530,611 1,001,019  
Deferred Tax Assets, Capital Loss Carryforwards $ 12,454,846 6,714,504  
Net operating loss carryforward, expiration date 2037    
Net operating loss carryforward term 20 years    
Deferred tax assets, net $ 31,427,925 20,361,140  
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 2,948,170 2,974,703  
Deferred tax asset, acquired in-process research and development, tax effected 2,481,070 2,405,997  
Orphan Drug [Member]      
Deferred Tax Assets, Operating Loss Carryforwards 791,151 427,343  
License Rights [Member] | CoNCERT Pharmaceuticals, Inc [Member]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities     $ 3,037,147
Deferred tax liability, intangible assets     11,038,929
Deferred tax liability, expenses     $ 1,782
In Process Research and Development [Member]      
Deferred tax asset, Purchase expensed in process research and development 572,713 8,743,517  
Deferred tax asset, acquired in-process research and development 9,316,230 8,743,517  
General and Administrative Expense [Member]      
Deferred tax asset, start-up expenditures 7,428,810 4,256,064  
Tax Effect [Member]      
Deferred tax asset, start-up expenditures 807,256 370,111  
Allocated stock based compensation 415,312 105,549  
Deferred tax asset, Purchase expensed in process research and development 75,073 2,405,997  
Deferred tax asset, intangible asset 288,339 216,974  
Deferred tax asset, start-up expenditures, tax effected 1,978,418 1,171,162  
Deferred tax assets capital loss carryforwards 3,376,415 1,847,664  
Deferred tax assets capital loss carryforwards 593,365 178,053  
Deferred tax asset, acquired in-process research and development, tax effected 2,481,070 2,405,997  
Share Based Compensation [Member]      
Deferred Tax Assets, Capital Loss Carryforwards $ 2,228,039 $ 647,055